DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Peter Lawson - 1 Relay's - 1 Lawson - 1 Yigal Nochomovitz - 1 Olema - 1 Nochomovitz - 1 Palazestrant - 1 palazestrant - 1
Top related locs:
Chicago Ohio –
Top related orgs:
Oncology - 2 Barclays - 1 Therapeutics - 1 Citi Research - 1 FDA - 1 CNN - 1 US Food and Drug Administration - 1 American Society of Clinical Oncology - 1

Search resuls for: "ribociclib"


3 mentions found


☆ Barclays upgrades a little-known biotech stock that it says can more than double
  + stars: | 2024-05-10 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
Barclays thinks Relay Therapeutics stock can benefit from progress in drug tests to get a proposed breast cancer treatment approved, boosting the stock. Relay stock has slumped 40% in 2024. "We believe the 2H update will help show the superior efficacy/safety profile for Relay's PI3Kalpha (RLY-2608) over existing PI3Kalpha inhibitors like alpelisib and inavolisib," Lawson said. Barclays sees a 70% chance of positive data emerging from an expanded Phase 1 study of RLY-2608 (+fulvestrant) in advanced HR+/HER2- breast cancer. That outcome, "all else equal, could potentially drive the stock up $5 while negative data could drive the stock down $2," the bank said.
Persons: Peter Lawson, Relay's, Lawson Organizations: Barclays, Therapeutics
☆ This little-known oncology stock could jump more than 70%, Citi says
  + stars: | 2024-01-30 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
Olema Oncology could be a standout player in developing therapies for women's cancers, particularly in breast cancer, according to Citi Research. The stock was flat in trading on Tuesday, but has fallen more than 16% so far this year. Last year, Olema shares soared more than 470% as the company released a series of positive updates, particularly about its lead investigational oncology drug palazestrant , Nochomovitz said. "We believe palazestrant has emerged as a highly promising CERAN/SERD with opportunities across multiple lines of ER+ breast cancer," Nochomovitz wrote in a Tuesday note. CDK4/6 inhibitors are drugs that are used to treat metastatic breast cancer, or advanced stage IV breast cancer, which has spread to other organs in the body far from the breast.
Persons: Yigal Nochomovitz, Olema, Nochomovitz, Palazestrant, palazestrant, ribociclib Organizations: Oncology, Citi Research, FDA
☆ Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows
  + stars: | 2023-06-02 | by ( Jen Christensen | ) edition.cnn.com   time to read: +6 min
CNN —A drug used in people in the early stage of the most common kind of breast cancer – HR+/HER2- breast cancer – significantly reduced the risk of the cancer returning after treatment, according to a new study. HR+/HER2- breast cancer has tested positive for progesterone and estrogen receptors and negative for HER2. Endocrine therapy generally works well, but for patients with HR+ or HER- breast cancer, there’s still a 10% to 40% chance that the cancer will come back, some studies show. The new trial found that when Kisqali is added to endocrine therapy, it reduces the risk of recurrence by 25% across a broad population of patients with early breast cancer. About 90% of patients who have breast cancer are diagnosed in the early stages.
Persons: there’s, Kisqali, ”, Dennis J, Slamon, Sara Tolaney, ” Tolaney, Anupama Goel, Goel, Dr, Sanjay Gupta, Alberto Montero, ” Montero, Montero Organizations: CNN, US Food and Drug Administration, American Society of Clinical Oncology, Novartis, UCLA, Comprehensive Cancer Center, Oncology, Dana, Farber Cancer Institute, Mount Sinai Tisch Cancer Center, CNN Health, UH Seidman Cancer Center, Case Western Reserve University School of Medicine Locations: Chicago, Ohio, –
0 next >>
Total: 3